How cost-effective are ovarian and breast cancer risk reduction strategies among women with pathogenic variants in individual cancer susceptibility genes (ie, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BRIP1)? The gene discussed is BRCA1; the disease is cancer.